55174-55-5Relevant academic research and scientific papers
Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection
-
Paragraph 1040; 1041, (2015/08/04)
The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5 and R6 are as described herein, compositions including the compounds and methods of using the compounds.
NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION
-
Page/Page column 123, (2015/09/23)
The invention provides novel compounds having the general formula (I) wherein R1, R2 R3, R4, R5 and R6 are as described herein, compositions including the compounds and methods of using the compounds in the treatment of the hepatitis B virus.
NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION
-
Page/Page column 53, (2016/04/26)
The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R6, X and Y are as described in the description and in the claims, as well as or pharmaceutically acceptable salts, or enantiomers, or diastereomers thereof. The invention also contains compositions including the compounds and methods of using the compounds.
Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs
-
Page 33, (2008/06/13)
The present invention comprises novel analogs of ecstasy-class compounds and novel ecstasy-class immunogens leashed out of, i.e., derived from, the methylenedioxy position. The invention also comprises unique monoclonal antibodies generated using MDO-leashed MDMA immunogens as well as unique conjugates and tracers. These antibodies, conjugates, and tracers are useful in immunoassays for the detection of ecstasy-class compounds in biological fluids.
Indoloisoquinolines. Syntheses, Steroid Hormone Receptor Binding Affinities, and Cytostatic Activity
Ambros, Reinhard,Schneider, Martin R.,Angerer, Silvia von
, p. 153 - 160 (2007/10/02)
A number of acetoxy-substituted 5,6-dihydroindoloisoquinolines were synthesized and tested for binding affinity for steroid hormone receptors.All of the derivatives bind to the estrogen receptor with RBA values ranging from 1.5 to 17 (17β-estradiol
